Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...